Sumatriptan

Generic Name: Sumatriptan

Brand Names: Imitrex, Onzetra, Sumavel, Tosymra, Treximet, Zembrace

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₁N_₃O_₂S

CAS Number: 103628-46-2

Unique Ingredient Identifier: 8R78F6L9VO

Background: Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted FDA approval on 28 December 1992.

Indication: A combination sumatriptan and naproxen tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older. Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults. One of the subcutaneous formulations of sumatriptan is also indicate...

Associated Conditions: Acute Migraine, Acute Cluster headaches

Associated Therapies: -

Clinical Trials

Treximet Early Intervention Adolescent Migraine

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: Treximet
Drug: Placebo

First Posted Date: 2009-11-19

Last Posted Date: 2016-05-04

Lead Sponsor: Premiere Research Institute

Target Recruit Count: 104

Registration Number: NCT01016678

Locations: 🇺🇸
Steve L. Linder, Dallas, Texas, United States
🇺🇸
Andrew Hershey, Cincinnati, Ohio, United States
🇺🇸
Premiere Research Institute, West Palm Beach, Florida, United States

and more 1 locations

Efficacy and Safety of BGG492 in the Treatment of Migraine

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: BGG492
Drug: Sumatriptan
Drug: Placebo

First Posted Date: 2009-05-04

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis

Target Recruit Count: 75

Registration Number: NCT00892203

Locations: 🇺🇸
California Clinical Trials, 1560 Chevy Chase Drive, Suite 140, Glendale, California, United States
🇺🇸
California Clinical Trials, 15625 Lakewood Boulevard, Paramount, California, United States
🇩🇪
Novartis Investigator Site, Munich, Germany

and more 1 locations

Treximet in Acute Migraine Headache: Assessing Cognitive Function

Not Applicable

Conditions: Migraine Headache
Cognitive Impairment

Interventions: Drug: Migraine rescue medication of choice
Drug: Treximet

First Posted Date: 2009-02-05

Last Posted Date: 2009-02-05

Lead Sponsor: Neurological Research Center

Target Recruit Count: 30

Registration Number: NCT00837044

Locations: 🇺🇸
The Neurological Research center, Inc, Bennington, Vermont, United States

Study in Participants With Acute Migraines Headaches

Phase 2

Terminated

Conditions: Migraine Headache

Interventions: Drug: LY2590443
Drug: Sumatriptan
Drug: Placebo injection
Drug: Placebo capsule

First Posted Date: 2008-12-09

Last Posted Date: 2020-05-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 120

Registration Number: NCT00804973

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norfolk, Virginia, United States

Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)

Phase 1

Completed

Conditions: Migraine Disorders

Interventions: Drug: telcagepant potassium
Drug: sumatriptan
Drug: sumatriptan placebo
Drug: telcagepant potassium placebo

First Posted Date: 2008-06-19

Last Posted Date: 2018-10-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT00701389

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2008-02-21

Last Posted Date: 2023-05-09

Lead Sponsor: Zogenix, Inc.

Target Recruit Count: 18

Registration Number: NCT00620425

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches

Phase 3

Completed

Conditions: Migraine Headaches

First Posted Date: 2007-02-12

Last Posted Date: 2007-02-12

Lead Sponsor: POZEN

Target Recruit Count: 1400

Registration Number: NCT00433732

Locations: 🇺🇸
Pozen, Inc., Chapel Hill, North Carolina, United States
🇺🇸
Little Rock Family Practice Clinic, Little Rock, Arkansas, United States

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches

Phase 3

Completed

Conditions: Migraine Headaches

First Posted Date: 2007-02-12

Last Posted Date: 2007-02-12

Lead Sponsor: POZEN

Target Recruit Count: 1200

Registration Number: NCT00434083

Locations: 🇺🇸
Pozen, Inc., Chapel Hill, North Carolina, United States
🇺🇸
Nashville Neuroscience Group, PC, Nashville, Tennessee, United States

Neuropeptides in the Humane Intra- og Extracerebral Circulation.

Not Applicable

Completed

Conditions: Healthy
Migraine

First Posted Date: 2006-11-15

Last Posted Date: 2008-05-14

Lead Sponsor: Danish Headache Center

Target Recruit Count: 16

Registration Number: NCT00399633

Locations: 🇩🇰
Danish Headache Center, Glostrup, Copenhagen, Copenhagen, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy